Clinical trial
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic…
NCT00252005 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00252005 |
|---|---|
| Title | Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study |
| Official title | Protocol CV185017: A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Deep-Vein Thrombosis |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Deep-Vein Thrombosis |
| Intervention type | Drug |
| Interventions | Apixaban |
| Enrollment | 520 |
| Start date | Nov 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Nov 11, 2005 |
| Last update posted | Mar 2, 2010 |
| Countries | Australia, Austria, Czechia, France, Israel, Italy, Netherlands, Poland, South Africa, Sweden, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: